AARD Key Statistics, Chart & Performance
The current stock price of AARD is 12.65 USD. In the past month the price decreased by -12.82%.
AARD Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to AARD.
AARD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AARD. While AARD has a great health rating, there are worries on its profitability.
AARD Financial Highlights
Over the last trailing twelve months AARD reported a non-GAAP Earnings per Share(EPS) of -2.53. The EPS decreased by -185.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.61% | ||
| ROE | -39.85% | ||
| Debt/Equity | 0 |
AARD Forecast & Estimates
17 analysts have analysed AARD and the average price target is 33.35 USD. This implies a price increase of 163.67% is expected in the next year compared to the current price of 12.65.
AARD Ownership
AARD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.53 | 965.082B | ||
| JNJ | JOHNSON & JOHNSON | 20.76 | 572.907B | ||
| MRK | MERCK & CO. INC. | 22.54 | 297.222B | ||
| PFE | PFIZER INC | 9.06 | 150.614B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.19 | 121.168B | ||
| ZTS | ZOETIS INC | 18.6 | 55.849B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.61 | 25.456B | ||
| VTRS | VIATRIS INC | 5.78 | 16.516B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.9 | 12.079B | ||
| AXSM | AXSOME THERAPEUTICS INC | 223.48 | 9.116B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AARD
Company Profile
Aardvark Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in San Diego, California and currently employs 33 full-time employees. The company went IPO on 2025-02-13. The firm targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. The company is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).
Company Info
AARDVARK THERAPEUTICS INC
4370 La Jolla Village Drive, Suite 1050
San Diego CALIFORNIA US
Employees: 33
Phone: 18582257696
AARDVARK THERAPEUTICS INC / AARD FAQ
What does AARD do?
Aardvark Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in San Diego, California and currently employs 33 full-time employees. The company went IPO on 2025-02-13. The firm targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. The company is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).
Can you provide the latest stock price for AARDVARK THERAPEUTICS INC?
The current stock price of AARD is 12.65 USD. The price increased by 12.05% in the last trading session.
Does AARD stock pay dividends?
AARD does not pay a dividend.
How is the ChartMill rating for AARDVARK THERAPEUTICS INC?
AARD has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does AARDVARK THERAPEUTICS INC have?
AARDVARK THERAPEUTICS INC (AARD) currently has 33 employees.
Can you provide the ownership details for AARD stock?
You can find the ownership structure of AARDVARK THERAPEUTICS INC (AARD) on the Ownership tab.